| PARP Inhibition for Gliomas (PI-4G or π4g) (NCT05297864) | University of Oklahoma | 2022-06-09 |
| Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma (NCT06090903) | Jonsson Comprehensive Cancer Center | 2022-04-14 |
| Natural Progesterone for the Treatment of Recurrent Glioblastoma (NCT05091866) | Emory University | 2022-04-11 |
| Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (NCT04729959) | National Cancer Institute (NCI) | 2022-03-11 |
| ASP8374 + Cemiplimab in Recurrent Glioma (NCT04826393) | Dana-Farber Cancer Institute | 2022-03-09 |
| GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients (NCT05191784) | Genexine, Inc. | 2022-01-26 |
| Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM (NCT05118776) | Ascletis Pharmaceuticals Co., Ltd. | 2022-01-21 |
| Sacituzumab Govitecan in Recurrent Glioblastoma (NCT04559230) | The University of Texas Health Science Center at San Antonio | 2022-01-06 |
| Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma (NCT05201326) | Ruijin Hospital | 2021-12-22 |
| Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG) (NCT05131711) | Beijing Tiantan Hospital | 2021-11-16 |
| Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (NCT04681677) | Xoft, Inc. | 2021-11-02 |
| Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma (NCT04888611) | Huashan Hospital | 2021-10-26 |
| Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma (NCT05017610) | Emory University | 2021-10-20 |
| Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma (NCT04717999) | UWELL Biopharma | 2021-09-01 |
| Role of Repeat Resection in Recurrent Glioblastoma (NCT04838782) | University of Alberta | 2021-08-26 |
| Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients (NCT05108012) | Royan Institute | 2021-08-01 |
| Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) (NCT04952571) | Beijing Sanbo Brain Hospital | 2021-06-27 |
| Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients (NCT04988750) | NaviFUS Corporation | 2021-05-23 |
| ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma (NCT04854044) | Jonsson Comprehensive Cancer Center | 2021-05-01 |
| Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma (NCT04590664) | Emory University | 2021-01-15 |
| Niraparib Combined With Radiotherapy in rGBM (NCT04715620) | Tianjin Huanhu Hospital | 2021-01-01 |
| Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd (NCT04740190) | The University of Hong Kong | 2021-01-01 |
| TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine (NCT04671459) | Prof. Franciszek Lukaszczyk Memorial Oncology Center | 2020-12-26 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy (NCT04417088) | InSightec | 2020-11-06 |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma (NCT04528680) | Northwestern University | 2020-10-29 |
| LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma (NCT04479241) | Istari Oncology, Inc. | 2020-10-21 |
| Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM (NCT04440358) | InSightec | 2020-10-13 |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults (NCT04323046) | Sabine Mueller, MD, PhD | 2020-10-02 |
| Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma (NCT04477200) | University of Michigan Rogel Cancer Center | 2020-08-05 |
| VB-111 in Surgically Accessible Recurrent/Progressive GBM (NCT04406272) | Dana-Farber Cancer Institute | 2020-08-01 |
| Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (NCT04469075) | Memorial Sloan Kettering Cancer Center | 2020-07-09 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients (NCT04657315) | CHA University | 2020-06-24 |
| Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence (NCT04013672) | David Peereboom | 2020-03-19 |
| Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma (NCT04205357) | Haukeland University Hospital | 2020-03-01 |
| Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (NCT04214392) | City of Hope Medical Center | 2020-02-26 |
| BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (NCT03914742) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-02-16 |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma (NCT04201873) | Jonsson Comprehensive Cancer Center | 2020-01-08 |
| Niraparib/TTFields in GBM (NCT04221503) | Abramson Cancer Center at Penn Medicine | 2019-12-30 |
| IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM (NCT04003649) | City of Hope Medical Center | 2019-12-02 |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma (NCT03014804) | Jonsson Comprehensive Cancer Center | 2019-12-01 |
| TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab (NCT03856099) | PharmAbcine | 2019-11-13 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults (NCT03893487) | Sabine Mueller, MD, PhD | 2019-08-07 |
| Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma (NCT04051606) | Case Comprehensive Cancer Center | 2019-07-31 |
| Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib (NCT04004975) | Shandong Cancer Hospital and Institute | 2019-06-25 |
| CD147-CART Cells in Patients With Recurrent Malignant Glioma. (NCT04045847) | Xijing Hospital | 2019-05-30 |
| BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (NCT03749187) | University of California, San Francisco | 2019-04-03 |
| MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma (NCT03896568) | M.D. Anderson Cancer Center | 2019-02-12 |
| TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma (NCT03722342) | PharmAbcine | 2019-01-16 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (NCT03782415) | MediciNova | 2018-12-29 |
| Feasibility of Individualized Therapy for Recurrent Glioblastoma (NCT03681028) | Jennifer Clarke | 2018-12-19 |
| Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma (NCT03430791) | Baptist Health South Florida | 2018-12-05 |
| 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma (NCT03732352) | Jonsson Comprehensive Cancer Center | 2018-11-28 |
| Mathematical Model-Adapted Radiation In Glioblastoma (NCT03557372) | Dana-Farber Cancer Institute | 2018-11-12 |
| Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms (NCT04044937) | Thomas Hope | 2018-10-29 |
| Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma (NCT03275558) | Center Trials & Treatment | 2018-07-17 |
| STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain (NCT01904123) | M.D. Anderson Cancer Center | 2018-07-13 |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (NCT03107780) | National Cancer Institute (NCI) | 2018-07-09 |
| Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (NCT03283631) | Gary Archer Ph.D. | 2018-05-30 |
| Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment (NCT03573986) | Abramson Cancer Center at Penn Medicine | 2018-04-18 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (NCT02974621) | National Cancer Institute (NCI) | 2017-12-07 |
| Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma (NCT03022578) | M.D. Anderson Cancer Center | 2017-11-07 |
| HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma (NCT03216499) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-09-14 |
| DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma (NCT03115333) | ECOG-ACRIN Cancer Research Group | 2017-07-25 |
| NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery (NCT03020017) | Northwestern University | 2017-05-25 |
| Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma (NCT03034135) | Cantex Pharmaceuticals | 2017-03-09 |
| BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab (NCT03020602) | Seema Nagpal | 2017-01-04 |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (NCT02101905) | National Cancer Institute (NCI) | 2016-11-07 |
| Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma (NCT02844439) | Kadmon Corporation, LLC | 2016-06-01 |
| Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma (NCT02661282) | M.D. Anderson Cancer Center | 2016-06-01 |
| Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (NCT02192359) | City of Hope Medical Center | 2016-04-05 |
| Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma (NCT03033524) | PharmAbcine | 2016-02-04 |
| Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (NCT02208362) | City of Hope Medical Center | 2015-05-18 |
| Pembrolizumab in Treating Patients With Recurrent Glioblastoma (NCT02337686) | M.D. Anderson Cancer Center | 2015-04-28 |
| Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma (NCT02340156) | SynerGene Therapeutics, Inc. | 2014-12-01 |
| Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) (NCT01925573) | University of Maryland, Baltimore | 2014-05-01 |
| A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (NCT02017717) | Bristol-Myers Squibb | 2014-02-07 |
| A Phase III Study of Re-Irradiation in Recurrent Glioblastoma (NCT01830101) | AHS Cancer Control Alberta | 2014-02-01 |
| FMISO PET Study of Glioblastoma (NCT02076152) | Massachusetts General Hospital | 2014-02-01 |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma (NCT03360708) | Mayo Clinic | 2013-11-27 |
| Bevacizumab w / Temozolomide PET & Vascular MRI For GBM (NCT01987830) | Massachusetts General Hospital | 2013-11-01 |
| Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma (NCT01849146) | National Cancer Institute (NCI) | 2013-10-24 |
| Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma (NCT01754350) | Johann Wolfgang Goethe University Hospital | 2013-05-01 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (NCT01609790) | National Cancer Institute (NCI) | 2012-06-04 |
| A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma (NCT01349036) | Daiichi Sankyo | 2011-12-03 |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (NCT01498328) | Celldex Therapeutics | 2011-12-01 |
| Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma (NCT01266031) | National Cancer Institute (NCI) | 2011-07-12 |
| BIBF 1120 in Recurrent Glioblastoma Multiforme (NCT01251484) | Ulrik Lassen | 2011-01-01 |
| A Panobinostat Presurgery (NCT01115036) | Duke University | 2010-04-01 |
| Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (NCT00777153) | AstraZeneca | 2008-10-01 |
| Ketogenic Diet for Recurrent Glioblastoma (NCT00575146) | University Hospital Tuebingen | 2007-12-01 |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas (NCT00586508) | Eli Lilly and Company | 2007-11-01 |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour (NCT00503204) | AstraZeneca | 2007-09-01 |
| Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (NCT00390299) | Mayo Clinic | 2006-10-23 |
| Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research (NCT00250887) | University of Zurich | 2005-07-01 |
| Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide (NCT00102648) | M.D. Anderson Cancer Center | 2004-12-21 |
| Individual Patient Compassionate Use of GX-I7 (NCT04289155) | Genexine, Inc. | |
| TVI-Brain-1 in Expanded Access Patient (NCT05936216) | TVAX Biomedical | |